1999
A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis
Small W, DeSimone‐Macchi D, Parker J, Sukerkar A, Hahn P, Rubin D, Zelch J, Kuhlman J, Outwater E, Weinreb J, Brown J, de Lange E, Woodward P, Arildsen R, Foster G, Runge V, Aisen A, Muroff L, Thoeni R, Parisky Y, Tanenbaum L, Totterman S, Herfkens R, Knudsen J, Laster R, Duerinckx A, Stillman A, Spritzer C, Saini S, Rofsky N, Bernardino M. A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal Of Magnetic Resonance Imaging 1999, 10: 15-24. PMID: 10398973, DOI: 10.1002/(sici)1522-2586(199907)10:1<15::aid-jmri3>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsGastrointestinal contrast agentAdverse eventsSite investigatorsGastrointestinal tract side effectsPatient diagnosisBlinded readersMore adverse eventsPhase III studyInflammatory bowel diseaseGroup of patientsPeptic ulcer diseaseML of placeboT2-weighted MRI scansMultisite clinical trialContrast agentsOral contrast agentAdditional diagnostic informationPlacebo patientsOral agentsIII studyBowel diseaseUlcer diseaseGastrointestinal pathologyLaboratory changesPhysical examination
1992
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky N, Weinreb J. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent. Magnetic Resonance Quarterly 1992, 8: 156-68. PMID: 1390058.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPN'-dipyridoxylethylenediamineClinical experienceNon-enhanced T1Significant adverse eventsEnhanced magnetic resonance imagingManganese NT2-weighted imagesAdverse eventsHepatocellular originClinical trialsContrast agentsHepatobiliary agentsResonance imagingLiver imagingFavorable resultsLesion detectionNew contrast agentsIssues of safetyImaging techniquesAgentsImagingOptimal methodNumerous strategiesHepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity.
Bernardino M, Young S, Lee J, Weinreb J. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992, 183: 53-8. PMID: 1549694, DOI: 10.1148/radiology.183.1.1549694.Peer-Reviewed Original ResearchConceptsMn-DPDPMore lesionsAdditional lesionsT1-weighted imagesDose groupSerious side effectsMagnetic resonance imagingT2-weighted imagesFocal hepatic diseaseN'-dipyridoxylethylenediamineIntravenous bolusHepatic diseaseMultiinstitutional studyPatientsSide effectsLesionsResonance imagingHepatic MRManganese NImaging parametersContrast agentsImagingGroupInfusionBolus
1991
Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine.
Sze G, Brant-Zawadzki M, Haughton V, Maravilla K, McNamara M, Kumar A, Aisen A, Dreisbach J, Bradley W, Weinreb J. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991, 181: 693-9. PMID: 1947084, DOI: 10.1148/radiology.181.3.1947084.Peer-Reviewed Original ResearchConceptsCentral nervous systemGadodiamide injectionNervous systemMR imagingSerious adverse eventsContrast material enhancementVisualization of lesionsMagnetic resonance imagingNeurologic statusAdverse eventsMulticenter studyLaboratory valuesPatientsResonance imagingVital signsLesionsUnenhanced imagesSpinePhase IIInjectionMaterial enhancementContrast agentsMR imagesGadolinium chelate complexesImaging